Sequential studies of complement activation in XXXX .

@entity1 @entity8 @entity6300 @entity1252 @entity1988 @entity177 @entity8428
C1 and C3 activation, measured as C1r-C1s-C1 inactivator C1s-C1r-C1IA complexes in serum and circulating @entity8428 were studied in serial samples from 33 @entity1 with @entity1252 . All @entity1 demonstrated exacerbations during observation periods of 10-30 months and were divided into groups according to principal clincal features (mild @entity1252 , severe extra-renal @entity1252 , and @entity1988 ). Increased C1 activation was consistently found during exacerbation. @entity8428 in plasma was a feature associated with severe disease flares. Activation of C1, but not of C3, was documented before flare-ups of disease activity, but such predictive information was mostly restricted to @entity1 with @entity8 . C2 cleavage in plasma, studied serially in a few @entity1 , appeared to be closely associated with C1 activation. Circulating immune complexes, measured with solid-phase @entity6300 assay, did not always increase before development of clinical manifestations. Remission of symptoms was paralleled by decreasing concentrations of C1r-C1s-C1IA and of, when present, @entity8428 . Similar findings were made for immune complexes but only in severe disease. Persisting @entity8428 was observed in 3 @entity1 , who subsequently developed @entity177 . @entity6300 levels were transiently low during flare-ups of @entity1988 , but otherwise the concentrations of @entity6300 , C4 and C3 did not show consistent patterns of variation in relation to disease activity.
